S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Are Gene Therapy Stocks The Market's Next Big Winners?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Are Gene Therapy Stocks The Market's Next Big Winners?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Are Gene Therapy Stocks The Market's Next Big Winners?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Are Gene Therapy Stocks The Market's Next Big Winners?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Insider Trading & Ownership

$0.31
0.00 (0.00%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.31
▼
$0.33
50-Day Range
$0.29
▼
$0.45
52-Week Range
$0.26
▼
$1.33
Volume
127,791 shs
Average Volume
161,099 shs
Market Capitalization
$18.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
8.00%
Number Of
Insiders Buying
(Last 12 Months)
5
Amount Of
Insider Buying
(Last 12 Months)
$56,480.00
Number Of
Insiders Selling
(Last 12 Months)
0
Get ONCT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ONCT Insider Buying and Selling by Quarter


Oncternal Therapeutics Insider Trades History

Export to Excel
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2023Gunnar F KaufmannInsiderBuy3,000$0.36$1,080.0094,726  
6/12/2023Gunnar F KaufmannInsiderBuy25,000$0.35$8,750.0091,726  
4/14/2023Salim YazjiInsiderBuy5,000$0.30$1,500.00164,676  
4/13/2023James B BreitmeyerCEOBuy100,000$0.29$29,000.00146,544  
4/13/2023Richard G VincentCFOBuy30,000$0.30$9,000.00156,859  
4/12/2023Chase C LeavittGeneral CounselBuy15,000$0.29$4,350.0096,901  
4/12/2023Salim YazjiInsiderBuy10,000$0.28$2,800.00149,676  
(Data available from 1/1/2013 forward)












ONCT Insider Trading Activity - Frequently Asked Questions

Who is on Oncternal Therapeutics's Insider Roster?

The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, and Salim Yazji. Learn more on insiders at ONCT.

What percentage of Oncternal Therapeutics stock is owned by insiders?

8.00% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings.

Which Oncternal Therapeutics insiders have been buying company stock?

The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($19,480.00), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($71,000.00), Richard G Vincent ($30,004.35), and Salim Yazji ($4,300.00).

How much insider buying is happening at Oncternal Therapeutics?

Insiders have purchased a total of 234,003 ONCT shares in the last 24 months for a total of $134,614.35 bought.


More Insider Trading Tools from MarketBeat

Related Companies:
Insider Tracking Tools:
Insider Trading By Country:
Latest Articles:
This page (NASDAQ:ONCT) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -